Literature DB >> 2224864

Down-regulated c-myb expression inhibits DNA synthesis of T-leukemia cells in most patients.

D Venturelli1, M T Mariano, C Szczylik, M Valtieri, B Lange, W Crist, M Link, B Calabretta.   

Abstract

We have investigated the functional relevance of c-myb expression for DNA synthesis in patients' T-leukemia cells. [3H]Thymidine incorporation assays of 32 patients' leukemia cells exposed in vitro to c-myb sense or antisense oligodeoxynucleotides served to define two groups of patients: a responder group whose leukemia cells showed 2- to 16-fold lower levels of [3H]thymidine incorporation in c-myb antisense-treated cultures than in c-myb sense-treated cultures (20 patients) and a nonresponder group whose cells showed comparable [3H]thymidine incorporation levels in either c-myb sense- or antisense-treated cultures (12 patients). Down-regulation of c-myb mRNA levels in cells exposed to c-myb antisense oligodeoxynucleotides was comparable in both groups of patients, indicating that differential sensitivity to c-myb antisense oligodeoxynucleotides was not due to differential uptake of these oligodeoxynucleotides. DNA polymerase alpha mRNA levels were down-regulated in cells from the responders but were unaffected in the nonresponder group. These results suggest that c-myb is required for DNA synthesis in cells of many but not all T-leukemia patients and that leukemia cells in which DNA synthesis is not inhibited despite down-regulation of c-myb expression may have undergone some genetic change(s) that obviate(s) the requirement for myb protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224864

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  1 in total

1.  Requirement of c-myb in T cell development and in mature T cell function.

Authors:  Yen K Lieu; Atul Kumar; Anthony G Pajerowski; Thomas J Rogers; E Premkumar Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-04       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.